Question 95: Was treatment given (since the date of last report)?
The questions below regarding prophylactic anti-infection and immunosuppressant drugs, refer to supportive therapy used to treat or prevent the sequelae (or condition as a result of the disease) such as infections, autoimmune issues, GVHD, etc. Additional questions ask about other significant treatments given to the recipient following the anti-infection and immunosuppresion therapy questions.
Indicate if the recipient received therapy since the date of the last report, including anti-infection drugs, immunosuppressive drugs, or any other significant and/or experimental therapies. If “yes,” continue with question 96. If “no,” continue with 167.
Questions 96-104 Prophylactic Drugs
Drug
Prophylactic drugs are used to prevent infection by a virus, bacteria, fungus, or parasite. Drugs started as a result of infection should not be reported as prophylactic drugs.
Indicate “yes” or “no” for each of the drug categories listed. If “yes,” continue with the subsequent questions regarding the stoppage of the prophylactic drug. If the drug was stopped, indicate “yes” and report the date the drug was stopped.
Antifungal drugs are used to prevent fungal infections. Common prophylactic antifungal drugs include fluconazole, caspofungin, voriconazole, etc.
Antiviral drugs are used to prevent viral infections. Common prophylactic antiviral drugs include acyclovir, ganciclovir, foscarnet, etc.
Co-trimoxazole (Bactrim, Septra) is a prophylactic drug used to prevent Pneumocystis jirovecii, a protozoan (i.e., parasitic) infection that colonizes the lungs of those with compromised immune systems.
Prophylactic drug stopped?
Indicate if the prophylactic drugs in each category were stopped. Prophylactic drugs stopped for a period of time shorter than one week should not be considered as “stopped.”
Date stopped
Report the date the last prophylactic drug in each category was stopped. If the exact date is not known, use the process described for reporting partial or unknown dates in General Instructions, Guidelines for Completing Forms.
Questions 105-164: Therapies
Post-transplant therapies for immune deficiencies may include immunosuppressive therapies to prevent or treat GVHD (maternal-, transfusion-, or HCT-associated), autoimmune conditions, etc.
Indicate “yes” or “no” for each of the drugs listed. If “yes,” continue with the subsequent questions regarding the stoppage of the therapy. If the drug was stopped, indicate “yes” and report the date the drug was stopped.
Therapy
Each of the drugs in questions 105-164 have immunosuppressive properties.
Corticosteroids may be given topically or systemically. Budesonide, which is ingested orally, is considered a topical drug.
If the recipient is given a monoclonal antibody, select “yes” for question 120 and specify the monoclonal antibody in questions 121-142. If the monoclonal antibody is not listed, specify the drug in question 142.
If the recipient is given an immunosuppressant that is not listed, select “yes” for question 161 and specify the other immunosuppressant in question 164.
Therapy stopped
Indicate if the therapy was stopped. Therapy that is stopped for a period of time shorter than one week should not be considered as “therapy stopped.”
Date stopped
Report the date the therapy was stopped. If the exact date is not known, use the process described for reporting partial or unknown dates in General Instructions, Guidelines for Completing Forms.
Questions 165-166: Did the recipient receive any other significant treatment(s) (since the date of last report)?
Recipients with immune deficiency may receive treatments other than what is listed above. Treatments may include enzyme replacement therapy such as PEG-ADA. Each immune deficiency may have their own unique treatments, including interferon, growth factors, enzyme replacement, or other therapies.
If the recipient had any other significant treatments since the date of last report, select “yes” and specify the treatments in question 166. If the recipient did not have additional significant treatments, select “no” and continue with question 167.
Section Updates:
| Question Number | Date of Change | Add/Remove/Modify | Description | Reasoning (If applicable) |
|---|---|---|---|---|
| . | . | . | . | . |
Need more help with this?
Don’t hesitate to contact us here.